FUSE-AI

FUSE-AI

Private
Hamburg, HamburgHealthcare & Life Scienceshttps://www.fuse-ai.de

Last Round

M&A

Dec 23, 2024

Est. Valuation

$88.34M

Momentum Score

50 /100

Company Overview

FUSE-AI GmbH is a German e-health company founded in 2017 and based in Hamburg. The company specializes in developing artificial intelligence (AI) and deep learning-based software solutions for the clinical sector, particularly for radiology. Its flagship product, 'Prostate.Carcinoma.ai', is an EU-certified medical software that assists radiologists by analyzing MRI scans to detect and classify prostate carcinomas, aiming to increase efficiency and diagnostic quality. The software is designed to be integrated into existing clinical software systems. The company's mission is to improve medical care through intelligent, clinically validated AI, providing more precise, faster, and cost-effective medical diagnoses. In late 2024, a proposed reverse takeover by Pineapple Power Corporation PLC was announced to facilitate a listing on the London Stock Exchange.

Sector

Healthcare & Life Sciences

Verticals

Medical AI, Medical Imaging, Healthcare Analytics

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Application

Keywords

radiology AImedical imaging AIprostate MRI analysisAI diagnosticssoftware as a medical deviceSaMDprostate segmentationPACS integrationpicture archiving and communication systemPACSEU MDR certificationclinical AIdigital healthchannel salesDICOM viewer

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

FUSE-AI Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

FUSE-AI Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
M&ADec 23, 2024
AcceleratorAug 3, 2023
AcceleratorNov 3, 2022
SeedOct 1, 2019

Key People

Founding team and executive leadership

Andreas Raguse

CTO

Executive Team

Leonard W.

Chief Technology Officer

Executive Team

Juri Rohde

COO Incl. Management, Business Development, Strategy, Etc., Head Of Operations Incl. Product Development, Head Of Q R (QMR, PRRC)

Executive Team

FUSE-AI Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 2, 2026

    AI-based prostate cancer diagnosis software now available in the European market.

FUSE-AI Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

FUSE-AI Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about FUSE-AI's valuation, stock price, and market status.

Firmographic Details

HeadquartersHamburg, Hamburg
Employee Range17
Year Founded2017
Last FundingDec 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.